BR112018069105A2 - pirimidinas e variantes das mesmas, e usos para tais - Google Patents
pirimidinas e variantes das mesmas, e usos para taisInfo
- Publication number
- BR112018069105A2 BR112018069105A2 BR112018069105A BR112018069105A BR112018069105A2 BR 112018069105 A2 BR112018069105 A2 BR 112018069105A2 BR 112018069105 A BR112018069105 A BR 112018069105A BR 112018069105 A BR112018069105 A BR 112018069105A BR 112018069105 A2 BR112018069105 A2 BR 112018069105A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidines
- variants
- present
- potential treatment
- provides
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000000033 Purinergic Receptors Human genes 0.000 abstract 1
- 108010080192 Purinergic Receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
a presente invenção fornece compostos de pirimidina de fórmula 1 e usos das mesmas, por exemplo, para o tratamento potencial de doenças associadas com receptores purinérgicos p2x. em certos aspectos, a presente invenção fornece antagonistas de p2x3 e/ou p2x2/3 que são úteis, por exemplo, para o tratamento potencial de doenças, condições e transtornos de órgãos viscerais, cardiovasculares e relacionados à dor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662313334P | 2016-03-25 | 2016-03-25 | |
US62/313,334 | 2016-03-25 | ||
PCT/US2017/023126 WO2017165255A1 (en) | 2016-03-25 | 2017-03-20 | Pyrimidines and variants thereof, and uses therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018069105A2 true BR112018069105A2 (pt) | 2019-01-29 |
BR112018069105B1 BR112018069105B1 (pt) | 2024-08-06 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
JP6902045B2 (ja) | 2021-07-14 |
MA44489A (fr) | 2019-01-30 |
KR20180128015A (ko) | 2018-11-30 |
KR102377805B1 (ko) | 2022-03-22 |
US20200239421A1 (en) | 2020-07-30 |
CA3018180A1 (en) | 2017-09-28 |
WO2017165255A1 (en) | 2017-09-28 |
AU2017237929B2 (en) | 2021-04-15 |
EP3433258B1 (en) | 2023-07-19 |
US11230532B2 (en) | 2022-01-25 |
RU2760733C2 (ru) | 2021-11-30 |
EP3433258A4 (en) | 2019-10-30 |
CN108779119B (zh) | 2022-02-08 |
MX2018011622A (es) | 2019-03-28 |
US20190055202A1 (en) | 2019-02-21 |
CN108779119A (zh) | 2018-11-09 |
JP2019510025A (ja) | 2019-04-11 |
US10662162B2 (en) | 2020-05-26 |
EP3433258A1 (en) | 2019-01-30 |
RU2018137032A3 (pt) | 2020-05-22 |
RU2018137032A (ru) | 2020-04-27 |
CA3018180C (en) | 2024-02-20 |
AU2017237929A1 (en) | 2018-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018011136A (es) | Pirimidinas y variantes de estas, y usos de estas. | |
MX2018011622A (es) | Pirimidinas y sus variantes, y usos de las mismas. | |
CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
CY1122265T1 (el) | Αντισωματα εναντι ταυ και χρησεις αυτων | |
CY1121359T1 (el) | Ενωσεις ετεροαρυλιου για αναστολη κινασης | |
CY1124918T1 (el) | Ρυθμιστες ccr2 | |
CL2021000163A1 (es) | Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139) | |
FR24C1010I1 (fr) | Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux | |
CL2018003556A1 (es) | Anticuerpos anti-ige. | |
BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
DK3506909T3 (da) | 4'-phosphatanaloger og oligonukleotider omfattende samme | |
BR112016025048A2 (pt) | compostos e composições como agonistas do receptor tipo toll7 | |
BR112020003865A8 (pt) | Composições farmacêuticas compreendendo sepiapterina e seus usos | |
BR112018000542A2 (pt) | composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr | |
SV2018005775A (es) | Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida | |
BR112018010564A2 (pt) | composições farmacêuticas compreendendo levodopa amida e usos das mesmas | |
CL2016002084A1 (es) | Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina. | |
CL2015000717A1 (es) | Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c. | |
ES2980935T3 (es) | Antagonista del receptor p2x3 y/o p2x2/3, composición farmacéutica que lo comprende y su uso | |
CL2019000050A1 (es) | Procesos para la preparacion de oxipicolinamidas 4 - alkoxi - (acil o aquil). | |
CY1123359T1 (el) | Τροποποιητες ετεροαρωματικου υπολοχεα nmda και χρησεις αυτων | |
BR112017022208A2 (pt) | sistema espinhal poliaxial expansível | |
CY1124540T1 (el) | Συνθεσεις και μεθοδοι που σχετιζονται με αγωνιστες 5-ht1f πυριδινοϋλοπιπεριδινης | |
CY1123013T1 (el) | Συνδυασμος των καθαρων ανταγωνιστων του υποδοχεα 5-ητ6 με τους αναστολεις της ακετυλοχολινεστερασης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 487/04 Ipc: C07D 487/04 (2006.01), C07D 239/48 (2006.01), C07D |
|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: AFFERENT PHARMACEUTICALS INC. (US) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/03/2017, OBSERVADAS AS CONDICOES LEGAIS |